{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T09:05:57Z","timestamp":1740128757587,"version":"3.37.3"},"reference-count":20,"publisher":"Oxford University Press (OUP)","issue":"suppl_5","funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,11,22]]},"DOI":"10.1093\/infdis\/jiy334","type":"journal-article","created":{"date-parts":[[2018,6,18]],"date-time":"2018-06-18T23:27:04Z","timestamp":1529364424000},"page":"S690-S697","source":"Crossref","is-referenced-by-count":8,"title":["The Past Need Not Be Prologue: Recommendations for Testing and Positioning the Most-Promising Medical Countermeasures for the Next Outbreak of Ebola Virus Infection"],"prefix":"10.1093","volume":"218","author":[{"suffix":"Jr","given":"Richard T","family":"Davey","sequence":"first","affiliation":[{"name":"Division of Intramural Research, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lori","family":"Dodd","sequence":"additional","affiliation":[{"name":"Division of Clinical Research, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Proschan","sequence":"additional","affiliation":[{"name":"Division of Clinical Research, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Jahrling","sequence":"additional","affiliation":[{"name":"Integrated Research Facility, NIAID, NIH, Frederick, Maryland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa","family":"Hensley","sequence":"additional","affiliation":[{"name":"Integrated Research Facility, NIAID, NIH, Frederick, Maryland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth","family":"Higgs","sequence":"additional","affiliation":[{"name":"Division of Clinical Research, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H Clifford","family":"Lane","sequence":"additional","affiliation":[{"name":"Division of Clinical Research, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2018,7,18]]},"reference":[{"volume-title":"Ebola data and statistics: situation summary","year":"2016","key":"key\n\t\t\t\t2018112203540489500_CIT0001"},{"key":"key\n\t\t\t\t2018112203540489500_CIT0002","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bcp.2014.11.008","article-title":"Ebola virus (EBOV) infection: therapeutic strategies","volume":"93","author":"De Clercq","year":"2015","journal-title":"Biochem Pharmacol"},{"key":"key\n\t\t\t\t2018112203540489500_CIT0003","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s40506-017-0130-z","article-title":"Discovering drugs for the treatment of Ebola virus","volume":"9","author":"Bixler","year":"2017","journal-title":"Curr Treat Options Infect Dis"},{"key":"key\n\t\t\t\t2018112203540489500_CIT0004","article-title":"Post-exposure treatments for Ebola and Marburg virus infections","author":"Cross","year":"2018","journal-title":"Nat Rev Drug Discov"},{"key":"key\n\t\t\t\t2018112203540489500_CIT0005","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1016\/j.molmed.2017.07.002","article-title":"Clinical evaluation of Ebola virus disease therapeutics","volume":"23","author":"Liu","year":"2017","journal-title":"Trends Mol Med"},{"key":"key\n\t\t\t\t2018112203540489500_CIT0006","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1177\/1740774515617740","article-title":"Trial design for evaluating novel treatments during an outbreak of an infectious disease","volume":"13","author":"Whitehead","year":"2016","journal-title":"Clin Trials"},{"key":"key\n\t\t\t\t2018112203540489500_CIT0007","doi-asserted-by":"crossref","first-page":"2350","DOI":"10.1056\/NEJMp1414145","article-title":"Evaluating Ebola therapies\u2013the case for RCTs","volume":"371","author":"Cox","year":"2014","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2018112203540489500_CIT0008","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1177\/1740774515616944","article-title":"Evaluating interventions for Ebola: the need for randomized trials","volume":"13","author":"Fleming","year":"2016","journal-title":"Clin Trials"},{"key":"key\n\t\t\t\t2018112203540489500_CIT0009","doi-asserted-by":"crossref","first-page":"4421","DOI":"10.1172\/JCI83162","article-title":"Ebola viral load at diagnosis associates with patient outcome and outbreak evolution","volume":"125","author":"de La Vega","year":"2015","journal-title":"J Clin Invest"},{"key":"key\n\t\t\t\t2018112203540489500_CIT0010","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1056\/NEJMoa1504874","article-title":"Clinical management of Ebola virus disease in the United States and Europe","volume":"374","author":"Uyeki","year":"2016","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2018112203540489500_CIT0011","doi-asserted-by":"crossref","first-page":"S84","DOI":"10.1093\/infdis\/jiv115","article-title":"State-of-the-art workshops on medical countermeasures potentially available for human use following accidental exposures to Ebola virus","volume":"212","author":"Jahrling","year":"2015","journal-title":"J Infect Dis"},{"key":"key\n\t\t\t\t2018112203540489500_CIT0012","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1089\/bsp.2009.0002","article-title":"Triage and management of accidental laboratory exposures to biosafety level-3 and -4 agents","volume":"7","author":"Jahrling","year":"2009","journal-title":"Biosecur Bioterror"},{"key":"key\n\t\t\t\t2018112203540489500_CIT0013","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nature13777","article-title":"Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp","volume":"514","author":"Qiu","year":"2014","journal-title":"Nature"},{"key":"key\n\t\t\t\t2018112203540489500_CIT0014","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1177\/1740774515620145","article-title":"Statistical considerations for a trial of Ebola virus disease therapeutics","volume":"13","author":"Proschan","year":"2016","journal-title":"Clin Trials"},{"key":"key\n\t\t\t\t2018112203540489500_CIT0015","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1093\/infdis\/jiw061","article-title":"Design of a randomized controlled trial for Ebola virus disease medical countermeasures: PREVAIL II, the Ebola MCM study","volume":"213","author":"Dodd","year":"2016","journal-title":"J Infect Dis"},{"key":"key\n\t\t\t\t2018112203540489500_CIT0016","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1056\/NEJMc1614625","article-title":"Trial of ZMapp for Ebola virus infection","volume":"376","author":"Davey","year":"2017","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2018112203540489500_CIT0017","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1126\/science.351.6268.12","article-title":"As Ebola epidemic draws to a close, a thin scientific harvest","volume":"351","author":"Cohen","year":"2016","journal-title":"Science"},{"key":"key\n\t\t\t\t2018112203540489500_CIT0018","doi-asserted-by":"crossref","first-page":"329ra33","DOI":"10.1126\/scitranslmed.aad9875","article-title":"Two-mAb cocktail protects macaques against the Makona variant of Ebola virus","volume":"8","author":"Qiu","year":"2016","journal-title":"Sci Transl Med"},{"key":"key\n\t\t\t\t2018112203540489500_CIT0019","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1038\/nature17180","article-title":"Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys","volume":"531","author":"Warren","year":"2016","journal-title":"Nature"},{"key":"key\n\t\t\t\t2018112203540489500_CIT0020","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1038\/nature13027","article-title":"Protection against filovirus diseases by a novel broad-spectrum nucleoside analogue BCX4430","volume":"508","author":"Warren","year":"2014","journal-title":"Nature"}],"container-title":["The Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jid\/article-pdf\/218\/suppl_5\/S690\/26688867\/jiy334.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,19]],"date-time":"2019-10-19T12:49:12Z","timestamp":1571489352000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jid\/article\/218\/suppl_5\/S690\/5055714"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7,18]]},"references-count":20,"journal-issue":{"issue":"suppl_5","published-online":{"date-parts":[[2018,7,18]]},"published-print":{"date-parts":[[2018,11,22]]}},"URL":"https:\/\/doi.org\/10.1093\/infdis\/jiy334","relation":{},"ISSN":["0022-1899","1537-6613"],"issn-type":[{"type":"print","value":"0022-1899"},{"type":"electronic","value":"1537-6613"}],"subject":[],"published-other":{"date-parts":[[2018,12,15]]},"published":{"date-parts":[[2018,7,18]]}}}